- Chancellor Michael F. Collins
- Joint Strategic Planning
- About UMMS
- Contact Us
- Senior Leadership
The U.S. Food and Drug Administration approved the start of a mid-stage clinical trial of BrainStorm Cell Therapeutics’ adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS). The Phase 2 trial will be launched initially at the University of Massachusetts Medical School.